GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Anadys Pharmaceuticals, Inc. (ANDS) [hlAlert]

Rating:
Buy ANDS
up 36.02 %

Anadys Pharmaceuticals, Inc. (ANDS) rated Buy by Merriman Curhan Ford

Posted on: Thursday,  Jan 8, 2009  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) on 01/08/2009, when the stock price was $2.72.
Since then, Anadys Pharmaceuticals, Inc. has gained 36.03% as of 11/23/2011's recent price of $3.70.
If you would have followed this Merriman Curhan Ford's recommendation on ANDS, you would have gained 36.02% of your investment in 1049 days.

Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/8/2009 8:25 AM Buy
None
2.72
as of 12/31/2009
1 Week down  -44.10 %
1 Month down  -44.10 %
3 Months down  -51.33 %
1 YTD down  -52.94 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy